EHA Library - The official digital education library of European Hematology Association (EHA)

Abstract: PB2213

Type: Publication Only

Background
Thrombophilia is a condition where the blood has an increased tendency to form clots. Blood clots can cause problems such as deep vein thrombosis (DVT) or pulmonary embolism. Natural coagulation inhibitors in hemostasis are Antithrombin III (ATIII), Protein S (PS) and Protein C (PC).Congenital AT III deficiency is an autosomal dominant disorder in which an individual inherits one copy which encodes AT III. This condition leads to increased risk of venous and arterial thrombosis. This form is most commonly diagnosed during childhood after a child has had a thrombotic event. Severe congenital AT III deficiency, in which the individual inherits 2 defective genes, is a rare autosomal recessive condition associated with increased thrombogenesis, typically noted in the neonatal period or early infancy. This condition is rarely compatible with life. Acquired AT III deficiency is a deficiency of antithrombin primarily due to consumption, such as disseminated intravascular coagulation (DIC).Protein S deficiency may be hereditary or acquired; the latter is usually due to hepatic diseases or a vitamin K deficiency. Protein S deficiency usually manifests clinically as venous thromboembolism (VTE).Protein C deficiency is a congenital or acquired condition that leads to increased risk for thrombosis. Congenital PC deficiency is one of several inherited thrombophilias, which are a heterogeneous group of genetic disorders associated with an elevated risk of venous thromboembolism.

Aims
The aim of this study is to measure AT III, P S and P C in patients from oncology department, urology department and the department of obstetrics and gynecology.

Methods
The study took place of observation at the general hospital of Patras (Greece) and included a total of 280 patients (male and female). The blood of patients was examined and the ATIII, P S and P C values were recorded. AT III measurement is a chromogenic determination based on an amydolitic method.  Moreover the control of   P C include the study of the functionality and antigenicity with chromogenic method. Also, the control of P S is based on the study of the functionality and the antigenicity of free P S (batch method).

Results
We studied 280 patients. From these patients, 200 were surgery patients from gynecological and urological department and 80 were patients from oncology department ( table 1 ). Results for surgical patients  were :  AT III deficiency 4 patients ( 2 %),    P C deficiency 2 patients ( 1 % )  and P S deficiency 1 patient ( 0,5 % ). Furthermore, results for oncological patients were:   AT III  deficiency 3 patients ( 3.75 %),  P C deficiency  2 patients ( 2,5 % ) and P S deficiency 1 patient ( 1,25%).  

total patients		AT III deficiency	P C deficiency	P S deficiency
	110 female	3(2,7%)	2(2%)	0(0%)
200 surgical
	90 male	1(1%)	0(0%)	1(1%)
	47 female	2(4%)	1(2,1%)	1(2,1%)
80 oncological
	33 male	1(3%)	1(3%)	0(0%)

 Table  1 

Conclusion
It is a fact that, either oncological   or   surgical patients are associated with a number of complications, mainly thrombosis. In addition deficiency in a classic coagulation factor is a high rick of venous thrombosis. The obvious conclusion to be drawn is that, measurement of AT III, P S and P C should be performed. Thus we should evaluate the impact of VTD or pulmonary embolism on the survival of these patients.

Session topic: E-poster

Keyword(s): Antithrombin, Protein C, Protein S, Thrombosis